ENXTPA:IPNPharmaceuticals
Ipsen (ENXTPA:IPN) Stock Looks Reasonable On Cash Flow Yet Rich On Earnings
Ipsen’s share price has more than doubled over the past five years, yet the valuation picture is split, with a Discounted Cash Flow (DCF) estimate pointing to meaningful upside while market multiples indicate the stock is not cheap.
Ipsen has returned 105.5% over 5 years, which puts extra focus on whether today's price already reflects its prospects in rare diseases and specialty care.
Recent agreements to acquire Memo Therapeutics and Kartos Therapeutics can support growth expectations in...